Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial

NCT06755684 is registered in ClinicalTrials.gov with Peng Zhang as lead sponsor.

NCT NCT06755684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06755684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial
Lead sponsor
Peng Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
November 7, 2024
Completion date
December 31, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, bevacizumab, carboplatin, egfr, locally advanced non-small cell lung cancer, non-small cell lung cancer, pemetrexed, tyrosine kinase inhibitor